[1] E. Tran, D.L. Longo, W.J. Urba, A Milestone for CAR T Cells, N Engl J Med 377 (2017) 2593-2596. 10.1056/NEJMe1714680.
[2] L. Halim, J. Maher, CAR T-cell immunotherapy of B-cell malignancy: the story so far, Ther Adv Vaccines Immunother 8 (2020) 2515135520927164. 10.1177/2515135520927164.
[3] K. Newick, S. O'Brien, E. Moon, S.M. Albelda, CAR T Cell Therapy for Solid Tumors, Annu Rev Med 68 (2017) 139-152. 10.1146/annurev-med-062315-120245.
[4] E.A. Chong, J.J. Melenhorst, S.F. Lacey, D.E. Ambrose, V. Gonzalez, B.L. Levine, C.H. June, S.J. Schuster, PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR, Blood 129 (2017) 1039-1041. 10.1182/blood-2016-09-738245.
[5] A. Heczey, C.U. Louis, B. Savoldo, O. Dakhova, A. Durett, B. Grilley, H. Liu, M.F. Wu, Z. Mei, A. Gee, B. Mehta, H. Zhang, N. Mahmood, H. Tashiro, H.E. Heslop, G. Dotti, C.M. Rooney, M.K. Brenner, CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma, Mol Ther 25 (2017) 2214-2224. 10.1016/j.ymthe.2017.05.012.
[6] C. Bourgeois, B. Rocha, C. Tanchot, A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory, Science 297 (2002) 2060-2063. 10.1126/science.1072615.
[7] A. Ara, K.A. Ahmed, J. Xiang, Multiple effects of CD40-CD40L axis in immunity against infection and cancer, Immunotargets Ther 7 (2018) 55-61. 10.2147/ITT.S163614.
[8] R.H. Vonderheide, J.P. Dutcher, J.E. Anderson, S.G. Eckhardt, K.F. Stephans, B. Razvillas, S. Garl, M.D. Butine, V.P. Perry, R.J. Armitage, R. Ghalie, D.A. Caron, J.G. Gribben, Phase I study of recombinant human CD40 ligand in cancer patients, J Clin Oncol 19 (2001) 3280-3287. 10.1200/JCO.2001.19.13.3280.
[9] R.H. Vonderheide, J.M. Burg, R. Mick, J.A. Trosko, D. Li, M.N. Shaik, A.W. Tolcher, O. Hamid, Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors, Oncoimmunology 2 (2013) e23033. 10.4161/onci.23033.
[10] A.K. Nowak, A.M. Cook, A.M. McDonnell, M.J. Millward, J. Creaney, R.J. Francis, A. Hasani, A. Segal, A.W. Musk, B.A. Turlach, M.J. McCoy, B.W. Robinson, R.A. Lake, A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma, Ann Oncol 26 (2015) 2483-2490. 10.1093/annonc/mdv387.
[11] Z. Zhang, D. Jiang, H. Yang, Z. He, X. Liu, W. Qin, L. Li, C. Wang, Y. Li, H. Li, H. Xu, H. Jin, Q. Qian, Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor, Cell Death Dis 10 (2019) 476. 10.1038/s41419-019-1711-1.
[12] J. He, Z. Zhang, S. Lv, X. Liu, L. Cui, D. Jiang, Q. Zhang, L. Li, W. Qin, H. Jin, Q. Qian, Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer, Cell Immunol 329 (2018) 31-40. 10.1016/j.cellimm.2018.04.007.
[13] S. Ramanayake, I. Bilmon, D. Bishop, M.C. Dubosq, E. Blyth, L. Clancy, D. Gottlieb, K. Micklethwaite, Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials, Cytotherapy 17 (2015) 1251-1267. 10.1016/j.jcyt.2015.05.013.
[14] R.P. Gladue, T. Paradis, S.H. Cole, C. Donovan, R. Nelson, R. Alpert, J. Gardner, E. Natoli, E. Elliott, R. Shepard, V. Bedian, The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice, Cancer Immunol Immunother 60 (2011) 1009-1017. 10.1007/s00262-011-1014-6.
[15] X. Wang, M. Mathieu, R.J. Brezski, IgG Fc engineering to modulate antibody effector functions, Protein Cell 9 (2018) 63-73. 10.1007/s13238-017-0473-8.
[16] P. Wang, W. Qin, T. Liu, D. Jiang, L. Cui, X. Liu, Y. Fang, X. Tang, H. Jin, Q. Qian, PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma, Immunobiology 225 (2020) 151850. 10.1016/j.imbio.2019.09.009.
[17] S. Li, N. Siriwon, X. Zhang, S. Yang, T. Jin, F. He, Y.J. Kim, J. Mac, Z. Lu, S. Wang, X. Han, P. Wang, Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors, Clin Cancer Res 23 (2017) 6982-6992. 10.1158/1078-0432.CCR-17-0867.
[18] S. Rafiq, O.O. Yeku, H.J. Jackson, T.J. Purdon, D.G. van Leeuwen, D.J. Drakes, M. Song, M.M. Miele, Z. Li, P. Wang, S. Yan, J. Xiang, X. Ma, V.E. Seshan, R.C. Hendrickson, C. Liu, R.J. Brentjens, Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo, Nat Biotechnol 36 (2018) 847-856. 10.1038/nbt.4195.
[19] Y.D. Mahnke, T.M. Brodie, F. Sallusto, M. Roederer, E. Lugli, The who's who of T-cell differentiation: human memory T-cell subsets, Eur J Immunol 43 (2013) 2797-2809. 10.1002/eji.201343751.
[20] C.E. Rolle, R. Carrio, T.R. Malek, Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy, Cancer Res 68 (2008) 2984-2992. 10.1158/0008-5472.CAN-07-3040.
[21] C. Berger, M.C. Jensen, P.M. Lansdorp, M. Gough, C. Elliott, S.R. Riddell, Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates, J Clin Invest 118 (2008) 294-305. 10.1172/JCI32103.
[22] K.A. Ahmed, L. Wang, M.A. Munegowda, S.J. Mulligan, J.R. Gordon, P. Griebel, J. Xiang, Direct in vivo evidence of CD4+ T cell requirement for CTL response and memory via pMHC-I targeting and CD40L signaling, J Leukoc Biol 92 (2012) 289-300. 10.1189/jlb.1211631.